Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

419
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
419
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
189
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

212
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
212
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

382
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
382
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

540
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
540
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

321
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
321

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time trends in strategies for postoperative Crohn's disease management and long-term surgical recurrence: ENEIDA registry data.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Characterization of the stages of chronic liver disease based on plasma proteins involved in systemic inflammation.

Revista espanola de enfermedades digestivas·2026
Same author

Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.

Therapeutic advances in gastroenterology·2026
Same author

Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.

Inflammatory bowel diseases·2026
Same author

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Alimentary pharmacology & therapeutics·2026
Same author

Monitoring prostate cancer under androgen-deprivation therapy: insights from the implementation of a clinical decision support system dashboard.

Frontiers in oncology·2026

Related Experiment Video

Updated: Sep 10, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.4K

Defining partial response in inflammatory bowel disease: a Delphi consensus and economic evaluation.

Iago Rodríguez-Lago1,2,3, Luis Menchén4,5, José Germán Sánchez-Hernández6

  • 1Hospital de Galdakao-Usansolo, Galdakao, Spain.

Therapeutic Advances in Gastroenterology
|August 21, 2025
PubMed
Summary

Defining partial responders in inflammatory bowel disease (IBD) is crucial for patient care. This study established consensus definitions for partial response in ulcerative colitis and Crohn's disease, aiding clinical decision-making.

Keywords:
IBDhealthcare costsresponse to therapy

More Related Videos

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

9.6K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K

Related Experiment Videos

Last Updated: Sep 10, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.4K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

9.6K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K

Area of Science:

  • Gastroenterology and Hepatology
  • Clinical Medicine
  • Inflammatory Bowel Disease Research

Background:

  • Therapeutic goals in inflammatory bowel disease (IBD) are evolving with new treatments and diagnostics.
  • Despite advancements, significant unmet clinical needs persist in IBD management.
  • A clear definition of treatment response is essential for optimizing patient care.

Purpose of the Study:

  • To establish a consensus definition for "partial responders" in clinical practice for IBD.
  • To differentiate patients who do not meet defined therapeutic objectives within the expected timeframe.
  • To provide clear criteria for assessing treatment efficacy in various IBD scenarios.

Main Methods:

  • A two-round Delphi consultation involving 60 IBD-specialized gastroenterologists in Spain.
  • A 22-item questionnaire addressing four clinical scenarios: moderate ulcerative colitis (UC), acute severe UC, luminal Crohn's disease (CD), and perianal CD.
  • Consensus defined as agreement by ⩾70% of panelists using a 7-point Likert scale; analysis of associated annual costs for partial responders versus remission.

Main Results:

  • Consensus was reached on definitions for partial response in UC and CD, incorporating clinical scores, biomarkers, and imaging/endoscopic findings.
  • Estimated annual costs for partial responders were significantly higher than for patients in remission: €2570.40 (UC) vs €820.20, €1607.30 (luminal CD) vs €718.0, and €2886.70 (perianal CD) vs €888.80.
  • Achieving prolonged remission could yield substantial savings (55%-70%) in non-pharmacological resource use and associated costs.

Conclusions:

  • Formal definitions for partial responders have been established across four key IBD clinical scenarios.
  • These definitions can aid healthcare professionals in clinical decision-making and patient management.
  • Improved patient care and potential cost savings are achievable through better identification and management of treatment response in IBD.